2018 - Online Interactive Update Course (en, sp, pt)

This page contains exclusive content for the member of the following sections: TTS, CTS, IPITA, ISODP, IXA, ITA, TID, IHCTAS, IPTA, SPLIT. Log in to view.

Treatment of a Rejection

6.1 - Emerging Therapies for Prevention and Treatment of Antibody Injury to Allografts

Presenter: Stanley, Jordan, , United States
Authors: Stanley Jordan

[en] Treatment of a rejection has its ‘ups and downs’ and although evidence has been found, the experts’ opinion still prevails on the current treatments. The classic and intricate cellular and anti-body mediated processes have different approaches, in part.

The dilemma for clinicians is to what extent treat recurring or resistant rejections, either partially or totally. Chronic rejection leads to difficulties and disagreements in its treatment.

How to continue and what maintenance therapy follow in a patient with a rejection - whether it has diminished or not with treatment- is also controversial. These aspects are addressed in the conferences and with the Forum in the present module.

[sp] El tratamiento del rechazo tiene zonas de avance y estancamiento, se han encontrado evidencias pero aún la opinión de expertos sigue rigiendo en mucho los tratamientos actuales. Los clásicos e intrincados procesos celulares y mediados por anticuerpos tienen abordajes diferentes en parte.

Un dilema para los clínicos es hasta dónde y cuánto tratar los rechazos recurrentes o resistentes parcial o totalmente. El rechazo crónico ofrece dificultades y desacuerdos en su tratamiento.

Cómo seguir y qué terapia de mantenimiento instalar en un paciente con rechazo, haya remitido o no con el tratamiento es también un punto de controversia.

Estos aspectos se abordan en las conferencias y foro de este módulo.

[pt] O tratamento da rejeição apresenta zonas de avanço e de dúvidas; existem diretrizes baseadas em evidências, mas a opinião de especialistas ainda prevalece em muitas decisões no tratamento atual. Os clássicos e intrincados processos mediados por células e por anticorpos demandam diferentes abordagens.

Um desafio para os clínicos é até onde levar o tratamento de episódios recorrentes ou resistentes de rejeição. Além disso, a rejeição crônica oferece controvérsias e incertezas em seu manejo.

Por fim, que terapia de manutenção seguir em um paciente com rejeição aguda tratada é também um ponto de debate.

Esses aspectos são abordados nas conferências e no fórum do presente módulo.

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6